Comparative proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate
Abstract
We have employed an inverse engineering strategy based on quantitative proteome analysis to identify changes in intracellular protein abundance that correlate with increased specific recombinant monoclonal antibody production (q Mab) by engineered murine myeloma (NS0) cells. Four homogeneous NS0 cell lines differing in q Mab were isolated from a pool of primary transfectants. The proteome of each stably transfected cell line was analyzed at mid‐exponential growth phase by two‐dimensional gel electrophoresis (2D‐PAGE) and individual protein spot volume data derived from digitized gel images were compared statistically. To identify changes in protein abundance associated with q Mab datasets were screened for proteins that exhibited either a linear correlation with cell line q Mab or a conserved change in abundance specific only to the cell line with highest q Mab. Several proteins with altered abundance were identified by mass spectrometry. Proteins exhibiting a significant increase in abundance with increasing q Mab included molecular chaperones known to interact directly with nascent immunoglobulins during their folding and assembly (e.g., BiP, endoplasmin, protein disulfide isomerase). 2D‐PAGE analysis showed that in all cell lines Mab light chain was more abundant than heavy chain, indicating that this is a likely prerequisite for efficient Mab production. In summary, these data reveal both the adaptive responses and molecular mechanisms enabling mammalian cells in culture to achieve high‐level recombinant monoclonal antibody production. © 2004 Wiley Periodicals, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PDI overexpression has shown positive results on productivity in the case of monoclonal antibodies in both CHO cells and NS0 cells.
“Its overexpression has shown positive results on productivity in the case of monoclonal antibodies in both CHO cells and NS0 cells (Smales et al., 2004;Mohan et al., 2007).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Smales et al., 2004
Cites
Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth
Ibarra, R. U., Edwards, J. S., & Palsson, B. O. (2002) · Nature · doi:10.1038/nature01149 · Cited by 857 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178 · see citing works
Ohya, T., Hayashi, T., Kiyama, E., Nishii, H., Miki, H., Kobayashi, K., Honda, K., Omasa, T., & Ohtake, H. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21758 · Cited by 96 · see citing works
Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells
Khoo, S. H. G., & Al‐Rubeai, M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22041 · Cited by 38 · see citing works
- Authors
- Smales, C. M., Dinnis, D. M., Stansfield, S. H., Alete, D., Sage, E. A., Birch, J. R., Racher, A. J., Marshall, C. T., & James, D. C.
- Affiliations
- University of Kent (GB)
- The University of Queensland (AU)
- Lonza (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- James, D.C.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2004-09-30
- Volume
- 88
- Issue
- 4
- Pages
- 474-488
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W4231639351
- Cited by
- 119
- References
- 1
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2021: 11 · 2020: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 8 · 2013: 8 · 2012: 4
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology and Bioengineering (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- quantitative proteomics, molecular chaperones, BiP, protein disulfide isomerase, antibody light chain, antibody heavy chain
- MeSH terms
- Adaptation, Physiological, Animals, Antibodies, Monoclonal, Multiple Myeloma, Neoplasm Proteins, Recombinant Proteins, Gene Expression Regulation, Neoplastic, Proteome, Gene Expression Profiling, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review